Table 3 Presence of a clinical response at 6 months by selected factors
Characteristics | Clinical response (%) | No clinical response (%) | p-value |
|---|---|---|---|
Age | 0.488 | ||
< 65 years old | 28 (63.6) | 16 (36.4) | |
≥ 65 years old | 19 (55.9) | 15 (44.1) | |
Gender | < 0.001 | ||
Female | 46 (71.9) | 18 (28.1) | |
Male | 1 (7.1) | 13 (92.9) | |
Degree of Cell Differentiation | 0.387 | ||
G I / G II | 40 (62.5) | 24 (37.5) | |
G III / G IV | 7 (50.0) | 7 (50.0) | |
Clinical Stage (UICC) | < 0.001 | ||
I - II | 31 (86.1) | 5 (13.9) | |
III A - III B | 16 (38.1) | 26 (61.9) | |
T stage | < 0.001 | ||
T 1 (≤2 cm) | 1 (16.7) | 5 (83.3) | |
T 2 (> 2 and ≤5 cm) | 4 (13.3) | 26 (86.7) | |
T 3 (> 5 cm) | 15 (50.0) | 15 (50.0) | |
T 4 (tumour invading adjacent organ) | 11 (91.7) | 1 (8.3) | |
N stage | 0.035 | ||
Negative | 40 (66.7) | 20 (33.3) | |
Positive | 7 (38.9) | 11 (61.1) | |
HPV | < 0.001 | ||
Positive | 47 (79.7) | 12 (20.3) | |
Negative | 0 (0.0) | 19 (100.0) | |
HIV | 0.063 | ||
Positive | 8 (42.1) | 11 (57.9) | |
Negative | 39 (66.1) | 20 (33.9) | |
P16 | < 0.001 | ||
Positive | 45 (78.9) | 12 (21.1) | |
Negative/borderline | 2 (9.5) | 19 (90.5) | |
TP53 | < 0.001 | ||
Mutant | 2 (9.5) | 19 (90.5) | |
Wild type | 45 (78.9) | 12 (21.1) |